Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065078 | 0.86 | SIRT2 (0.47) | ENPP1SIRT2SIRT1SIRT3DYRK1A | |
| SCHEMBL4069719 | 0.84 | SUV39H2 (0.48) | ENPP1SIRT2SIRT1SIRT3MTNR1B | |
| SCHEMBL4069637 | 0.81 | SIRT2 (0.47) | SIRT2SIRT1SIRT3SUV39H2 | |
| SCHEMBL24392505 | 0.80 | EHMT2 (0.49) | NCF1SIRT2SIRT1SIRT3SUV39H2 | |
| SCHEMBL29589077 | 0.80 | EHMT2 (0.49) | NCF1SIRT2SIRT1SIRT3SUV39H2 | |
| SCHEMBL4066233 | 0.80 | NCF1 (0.62) | NCF1ENPP1MTNR1BKMT2AMEN1 | |
| SCHEMBL16020346 | 0.79 | CKS1B (0.49) | NCF1SIRT2SIRT1SIRT3 | |
| SCHEMBL28614808 | 0.79 | CHRM4 (0.50) | — | |
| SCHEMBL29691616 | 0.77 | SIRT2 (0.47) | ENPP1SIRT2SIRT1SIRT3SUV39H2 | |
| SCHEMBL24601078 | 0.77 | SIRT2 (0.47) | ENPP1SIRT2SIRT1SIRT3SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605938-B1 | Antibacterial derivatives of napthydrin and quinoline | GLAXO GROUP LTD (GB) | 2009-02-11 | — | — | EP | disclosed |
| EP-1605938-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20060189601-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
| EP-1605938-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004087145-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189601-A1 | Antibacterial agents | NQO2, NRDC, IFNG | NCF1 4/4885ENPP1 577/4885SIRT2 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.